MediWound Closes $17.25 Million Share Sale: How Dilution Works, With MDWD as the Example
MediWound sold 1.38 million shares at $12.50, below its $13.33 Nov. 5 close. The stock fell 6.13% that day and rose 6.9% Friday on light volume. A walk through how a priced offering can weigh on a share price.

MediWound Ltd. (NASDAQ: MDWD) said at 2:01 a.m. ET on Friday, Nov. 6, before pre-market trading began, that it closed its public offering of 1,380,000 ordinary shares at $12.50 each. Gross proceeds were $17.25 million, and the total includes 180,000 shares from the underwriter's fully exercised option. The company said it will use the money for general corporate purposes and working capital.
Shares dipped on filing day, then recovered after the close
MDWD fell 6.13% on Thursday, Nov. 5, the day the company filed its prospectus supplement, and rebounded 6.9% on Friday. The sale was priced below where the stock traded, which is the setup that makes offerings a textbook case of dilution.
How a priced offering works, and why it can weigh on a stock
When a listed company needs cash, it can sell new shares through an underwriter, a bank that buys the shares and resells them to investors. In a "bought deal," the bank commits to the purchase up front. The company files a prospectus supplement with the terms, and the shares usually sell at a price below the recent trading level to attract buyers.
Existing shareholders feel this in two ways. The first is dilution: the company is now split across more shares, so each share represents a smaller slice of earnings and assets, unless the new cash adds at least as much value. The second is supply: new shares reach the market at once, and the offering price becomes a reference point that traders compare with the quote.
An "option" (also called an overallotment) lets the underwriter buy extra shares at the same price within a set period. MediWound's underwriter used its option in full.
What MDWD's prices did around the sale
MediWound announced the offering on Nov. 4 as a $15 million deal. The stock closed that day at $14.20, up 6.05%, after a session high of $14.32. It then fell to $13.33 on Nov. 5, its biggest one-day drop in the sessions from Oct. 8 on. The $12.50 offering price was below that close.
On Friday there were no pre-market trades (the session before the 9:30 a.m. ET open). The stock traded between $13.34 and $14.29 in the regular session and closed at $14.25, up 6.9% from Thursday's close. Volume was 82,450 shares, against a 10-day average of 145,423, or 0.68 times normal. After-hours trading was a single share at $14.25.
From Oct. 8 through Nov. 5 the stock gained 7.33%, with a low of $11.80 on Oct. 26.
The sale against the company's size
MediWound's float, the shares available to trade, is about 9.87 million, and its market capitalization is about $183.97 million. Set against that float, the 1,380,000 new shares are a sizeable addition. The $17.25 million raised is well under a tenth of the market value.
The company did not disclose net proceeds (after fees) or the underwriter's name in the release. The shares were sold under a shelf registration on Form F-3, a filing that lets a company register securities in advance and sell them when it chooses.
Bottom line
MDWD dropped on the day the discounted sale was filed and regained the loss on Friday, when volume was below average. A single session does not show how long dilution weighs on the price.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




